{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:05:32Z","timestamp":1789833932221,"version":"4.0.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Toripalimab, a specific immune checkpoint inhibitor targeting the programmed death 1 (PD-1) receptor, represents a novel immunotherapeutic approach for advanced nasopharyngeal carcinoma, showing promising curative potential. However, it is not without drawbacks, as some patients experience immune-related adverse events (irAEs) associated with this treatment, and there remains a limited body of related research. Here, we present a case of advanced nasopharyngeal carcinoma in a patient who developed colitis as an irAE attributed to Toripalimab. Subsequent to Toripalimab treatment, the patient achieved complete remission. Notably, the development of colitis was accompanied by inflammatory manifestations evident in colonoscopy and pathology results. Further investigation revealed cytomegalovirus (CMV) infection, detected through immunohistochemistry in 11 colon biopsies. Subsequent treatment with ganciclovir and steroids resulted in symptom relief, and colonoscopy indicated mucosal healing. Our case highlights the association between irColitis induced by Toripalimab and CMV infection. Toripalimab demonstrates remarkable efficacy in treating advanced nasopharyngeal carcinoma, albeit with a notable risk of irAEs, particularly in the form of colitis. The link between symptoms and endoscopic pathology findings in irColitis is noteworthy. Standardized biopsy procedures can effectively confirm the diagnosis of CMV infection. Our findings may provide valuable guidance for managing acute CMV infection and irAEs associated with Toripalimab in the treatment of nasopharyngeal carcinoma in the future.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1298902","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T03:06:57Z","timestamp":1700795217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis"],"prefix":"10.3389","volume":"14","author":[{"given":"Canhua","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.019","article-title":"Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis","volume":"86","author":"Franklin","year":"2017","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.06.014","article-title":"Nocardiosis in a patient with anti-PD-1-associated colitis treated with infliximab","volume":"101","author":"Glutsch","year":"2018","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46737","DOI":"10.1038\/srep46737","article-title":"Pluronic based beta-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease","volume":"7","author":"Collins","year":"2017","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1596513","article-title":"Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy","volume":"11","author":"Liu","year":"2019","journal-title":"MAbs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"109437","DOI":"10.1016\/j.biopha.2019.109437","article-title":"Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy","volume":"120","author":"Liu","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.dld.2005.01.011","article-title":"Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection","volume":"37","author":"Maconi","year":"2005","journal-title":"Dig Liver Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3748\/wjg.v13.i5.754","article-title":"Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan","volume":"13","author":"Minami","year":"2007","journal-title":"World J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.10.022","article-title":"Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosupressants due to checkpoint inhibitor-induced hepatitis","volume":"80","author":"Malek","year":"2020","journal-title":"J Infect"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000577","article-title":"Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"B16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12879-017-2319-7","article-title":"Cytomegalovirus, Epstein-Barr virus and varicella zoster virus infection in the first two years of life: a cohort study in Bradford, UK","volume":"17","author":"Pembrey","year":"2017","journal-title":"BMC Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000556","article-title":"Detection of cytomegalovirus in patients with inflammatory bowel disease: where to biopsy and how many biopsies","volume":"21","author":"McCurdy","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101405","article-title":"The inflammasome NLRs in immunity, inflammation, and associated diseases","volume":"29","author":"Davis","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0782-y","article-title":"CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption","volume":"26","author":"Harper","year":"2020","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12328-020-01276-4","article-title":"Collagenous colitis and atezolizumab therapy: an atypical case","volume":"14","author":"Gallo","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of I-immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1298902\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T03:06:59Z","timestamp":1700795219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1298902\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2023.1298902"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1298902","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"article-number":"1298902"}}